Company D was a development-stage industrial biotech company that had recently completed a very successful IPO in a shaky overall market. Stern IR was responsible for heavily ramping up the IR program, to help maintain the visibility the company had achieved through the IPO process, to get more investors into the stock and to keep its existing shareholders once the lockup expired.
- Identify and actively introduce the company to new investors.
- Maintain visibility with investors who did not buy shares at the IPO roadshow.
- Maintain strong relationships with insiders and investors who bought shares on the IPO.
- Develop and maintain key messages and corporate collateral that would focus the story and resonate with the targeted investment community.
- Maximize upcoming news announcements.
- Conducted quantitative targeting to identify investors that would be likely to be interested in the company given their positions in other industrial biotech peers.
- Performed outreach to investors to introduce them to the company and its investment merits.
- Scheduled a robust calendar of IR activities, including a mix of IR conferences and bank-sponsored and self-managed roadshows throughout the U.S. and Europe.
- Instituted proactive outreach including IR email lists and management call lists for all news announcements.
- Heavily targeted new analyst coverage to gain visibility with additional investors.
- Hosted a NYC-based investor and analyst day to dive deep into the story.
- In the quarter following the IPO, 10 major institutions targeted by Stern IR became new shareholders, including AllianceBernstein, BlackRock, Deutsche Asset Management, ING and Manulife.
- The company was invited to participate in 15 investor conferences in the year following the IPO.
- The company’s NYC analyst day drew 40 attendees and 85 webcast participants.
- 1 non-syndicate firm initiated on the company, with a Buy rating.